- Home
- DTSS vs PRTG Comparison
DTSS vs PRTG Comparison
Compare DTSS & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- PRTG
- Stock Information
- Founded
- DTSS 2014
- PRTG 1973
- Country
- DTSS China
- PRTG British Virgin Islands
- Employees
- DTSS N/A
- PRTG N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- PRTG Oil & Gas Production
- Sector
- DTSS Technology
- PRTG Energy
- Exchange
- DTSS Nasdaq
- PRTG Nasdaq
- Market Cap
- DTSS 16.5M
- PRTG 17.7M
- IPO Year
- DTSS N/A
- PRTG N/A
- Fundamental
- Price
- DTSS $1.96
- PRTG $5.42
- Analyst Decision
- DTSS
- PRTG
- Analyst Count
- DTSS 0
- PRTG 0
- Target Price
- DTSS N/A
- PRTG N/A
- AVG Volume (30 Days)
- DTSS 55.1K
- PRTG 19.7K
- Earning Date
- DTSS 09-25-2025
- PRTG 08-26-2025
- Dividend Yield
- DTSS N/A
- PRTG N/A
- EPS Growth
- DTSS N/A
- PRTG N/A
- EPS
- DTSS N/A
- PRTG N/A
- Revenue
- DTSS $56,255,129.00
- PRTG N/A
- Revenue This Year
- DTSS N/A
- PRTG N/A
- Revenue Next Year
- DTSS N/A
- PRTG N/A
- P/E Ratio
- DTSS N/A
- PRTG N/A
- Revenue Growth
- DTSS 144.20
- PRTG N/A
- 52 Week Low
- DTSS $1.63
- PRTG $2.10
- 52 Week High
- DTSS $3.55
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- DTSS 43.05
- PRTG 40.80
- Support Level
- DTSS $1.91
- PRTG $5.65
- Resistance Level
- DTSS $2.17
- PRTG $6.40
- Average True Range (ATR)
- DTSS 0.11
- PRTG 0.46
- MACD
- DTSS -0.01
- PRTG 0.03
- Stochastic Oscillator
- DTSS 18.06
- PRTG 10.90
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.